Preparation and evaluation of 131I-quercetin as a novel radiotherapy agent against dedifferentiated thyroid cancer
- 27 December 2016
- journal article
- research article
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 311 (3) , 1697-1708
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundations of China (81271526)
- National Science and Technology Support Program (2014BAA03B00)
- National Fund for Fostering Talents of Basic Science (J1210004)
- University of Macau Research Fund (SRG2014-00025-ICMS-QRCM)
This publication has 32 references indexed in Scilit:
- Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid CarcinomaThyroid®, 2014
- Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatmentTumor Biology, 2013
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- Combined RNA Interference of Hexokinase II and 131I-Sodium Iodide Symporter Gene Therapy for Anaplastic Thyroid CarcinomaJournal of Nuclear Medicine, 2011
- Quercetin and Cancer ChemopreventionEvidence-Based Complementary and Alternative Medicine, 2011
- Tumor-Targeted Radionuclide Imaging and Therapy Based on Human Sodium Iodide Symporter Gene Driven by a Modified Telomerase Reverse Transcriptase PromoterHuman Gene Therapy, 2008
- Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid StunningCancer Research, 2007
- Peroxisome Proliferator–Activated Receptor γ as a Molecular Target of Resveratrol-Induced Modulation of Polyamine MetabolismCancer Research, 2006
- In Vitro and In Vivo Properties of a Human Anaplastic Thyroid Carcinoma Cell Line Transfected with the Sodium Iodide Symporter GeneThyroid®, 2004
- Synthesis of iodine‐123 labeled quercetin and catechin as radical seeking agentsJournal of Labelled Compounds and Radiopharmaceuticals, 2001